Naegleria infection medical therapy

Naegleria Infection Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Naegleria Infection from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Naegleria infection medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Naegleria infection medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Naegleria infection medical therapy
CDC on Naegleria infection medical therapy
Naegleria infection medical therapy in the news
Blogs on Naegleria infection medical therapy
Directions to Hospitals Treating Naegleria infection
Risk calculators and risk factors for Naegleria infection medical therapy

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Eye and skin infections caused by Acanthamoeba spp. are generally treatable. The treatment of choice is topical use of polyhexamthylene biguanide (PHMB) or chlorhexidene gluconate with or without Brolene. Although most cases of brain (CNS) infection with Acanthamoeba have resulted in death, patients have recovered from the infection with proper treatment. Amphotericin B has been successfully used in some cases to treat PAM caused by Naegleria fowleri.

References

Template:WH Template:WS